Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Cobimetinib · 1 trial · 8 indications
Will be estimated with a 95% confidence interval (CI).
| Arm | Type | Description |
|---|---|---|
| Arm Olaparib | EXPERIMENTAL | Patients receive olaparib PO BID on days 1-10 in the absence of disease progression or unacceptable toxicity. Within 12-24 hours, patients undergo biopsy or surgery as clinically appropriate per institutional standards for management of patient's disease. (Arm Closed as of 8/12/2024) |
| Arm Cobimetinib | EXPERIMENTAL | Patients receive cobimetinib PO QD on days 1-10 in the absence of disease progression or unacceptable toxicity. Within 12-24 hours, patients undergo biopsy or surgery as clinically appropriate per institutional standards for management of patient's disease. (Arm Closed as of 8/12/2024) |
| Arm Onvansertib | EXPERIMENTAL | Patients receive onvansertib PO QD on days 1-10 in the absence of disease progression or unacceptable toxicity. Within 12-24 hours, patients undergo biopsy or surgery as clinically appropriate per institutional standards for management of patient's disease. (Arm Closed as of 8/12/2024) |
| Arm Azenosertib | EXPERIMENTAL | Patients receive azenosertib PO QD on days 1-10 in the absence of disease progression or unacceptable toxicity. Within 12-24 hours, patients undergo biopsy or surgery as clinically appropriate per institutional standards for management of patient's disease. |
| Arm AZD5305 | EXPERIMENTAL | Patients receive AZD5305 PO QD on days 1-10 in the absence of disease progression or unacceptable toxicity. Within 12-24 hours, patients undergo biopsy or surgery as clinically appropriate per institutional standards for management of patient's disease. |
| Arm Tremelimumab | EXPERIMENTAL | Patients receive tremelimumab IV over 60 minutes one-time. Within 12-24 hours of cycle completion, patients undergo biopsy or surgery as clinically appropriate per institutional standards for management of patient's disease. |
| Name | Type | Description |
|---|---|---|
| Cobimetinib | DRUG | Given PO |
| Olaparib | DRUG | Given PO |
| Onvansertib | DRUG | Given PO |
| Azenosertib | DRUG | Given PO |
| Saruparib | DRUG | Given PO |
| Tremelimumab | BIOLOGICAL | Given IV |
Inclusion Criteria: * Ability to understand and the willingness to sign a written informed consent document * Age \>= 18 years * Eastern Cooperative Oncology Group (ECOG) performance status of 0-2 * Clinically-confirmed diagnosis of resectable, borderline resectable, locally-advanced or metastatic ...
Cobimetinib is being studied for use in locally advanced pancreatic ductal adenocarcinoma, as well as metastatic, stage II, III, and IV pancreatic cancer, and resectable, borderline resectable, and unresectable pancreatic ductal adenocarcinoma. It is an investigational small molecule kinase inhibitor in Phase 1 clinical development.
Cobimetinib is a small molecule that belongs to the -tinib class of kinase inhibitors. It is being investigated for its ability to inhibit specific kinase pathways involved in cancer cell growth and survival, particularly in pancreatic ductal adenocarcinoma.
Cobimetinib is being developed by Cardiff Oncology, Inc., a biopharmaceutical company traded on the NASDAQ under the ticker symbol CRDF. The company is conducting clinical trials to evaluate the drug's safety and efficacy in patients with pancreatic cancer.
Cobimetinib is in Phase 1 clinical development. It is an investigational drug and has not been approved by the FDA. The ongoing trial is an early Phase 1 study that is currently recruiting participants in the United States.
Cobimetinib is being evaluated in clinical trial NCT04005690, titled "Targeted Pathway Inhibition in Patients With Pancreatic Cancer." This early Phase 1 study is recruiting 90 participants with various stages of pancreatic ductal adenocarcinoma in the United States, with a minimum age of 18 years.
Cobimetinib is the generic name for the drug also known as Cotellic. In the context of this development program, Cardiff Oncology is investigating cobimetinib for pancreatic cancer, though the drug is also known by its brand name in other settings.